You are currently viewing our desktop site, do you want to download our app instead?
Moneyweb Android App Moneyweb iOS App Moneyweb Mobile Web App

NEW SENS search and JSE share prices

More about the app

Pfizer/BioNTech strike SA Covid-19 manufacturing deal with Biovac

To process and distribute over 100 million doses a year of their Covid-19 vaccine for the African Union beginning in 2022.
Image: Bloomberg

Pfizer Inc and BioNTech SE on Wednesday said they had struck a deal for South Africa’s Biovac Institute to process and distribute over 100 million doses a year of their Covid-19 vaccine for the African Union beginning in 2022.

Technical transfer, on-site development and equipment installation activities will begin immediately, they said. Biovac, a public-private partnership focused on vaccine production, will receive Covid-19 vaccine drug substance made in plants in Europe, and will begin so-called fill-finish operations, the last stage of drug manufacturing and packaging, in 2022.

Moneyweb Insider INSIDERGOLD

Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process.

Choose an option:

R63 per month
R630 per year SAVE R126

You will be redirected to a checkout page.
To view all features and options, click here.

A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership.

Click here for more information.

Pfizer announced the partnership ahead of a speech by Chief Executive Albert Bourla at a World Trade Organisation (WTO) Summit.

WTO members have been in talks for months on waiving drug firms’ intellectual property (IP) rights for Covid-19 vaccines. Most developing countries support the waiver but several wealthy countries remain strongly opposed, saying it will deter research that allowed Covid-19 vaccines to be produced so quickly.

In his prepared remarks, Bourla made a plea for the group to maintain the current IP rules.

“Weakening IP rules will only discourage the type of unprecedented innovation which brought vaccines forward in record time and make it harder for companies to collaborate going forward,” Bourla said.

Last month, the World Health Organisation said it was setting up a hub, or training facility, in South Africa to give companies there the know-how and licenses to produce Covid-19 vaccines. Biovac was one of the initial participants in the hub.

Biovac has partnered with Pfizer since 2015 to manufacture and distribute its Prevenar 13 pneumonia vaccine.

COMMENTS   1

You must be signed in to comment.

SIGN IN SIGN UP

Voila – another bottle filling company in empowered hands.
Maybe competition for SAB ne !!

End of comments.

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR
BTC / USD

Podcasts

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / LISTEN LIVE SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us:

Search Articles: Advanced Search
Click a Company: